Clinical trials: Ocular Hypertension (OH)
Primary Open Angle Glaucoma or Ocular Hypertension
A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study
The purposes of this study are to investigate the effect of intraocular pressure lowering efficacy and safety of DE-117 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension who are…
- Trial name
- NCT02822742
- Testing
- DE-117 ophthalmic solution, Latanoprost ophthalmic solution 0.005%
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Open Angle Glaucoma, Ocular Hypertension
Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH
This study is a double-masked, randomized, parallel group study in patients with open angle glaucoma or ocular hypertension. The aim of this study is to verify the efficacy of the fixed combination of Latanoprost 50 mcg / mL /…
- Trial name
- NCT01721707
- Testing
- Latanoprost+Brinzolamide combination, Latanoprost
- Where
- Brazil
- Sponsor
- Adapt Produtos Oftalmológicos Ltda.
Glaucoma,Open-Angle, Ocular Hypertension (OH)
Transscleral Selective Laser Trabeculoplasty Project
The purpose of this clinical trial is to determine how safe and effective (how well it works) the ELLEX TSLT device is for the treatment of Glaucoma and Ocular Hypertension using Transscleral Selective Laser Trabeculoplasty.
- Trial name
- TSLT project (NCT06833060)
- Testing
- Selective Laser Trabeculoplasty
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Lumibird Medical (Quantel Medical, Ellex Medical, Optotek)
Open Angle Glaucoma, Ocular Hypertension
DuoTrav APS Versus XALACOM® in Ocular Surface Health
To demonstrate superiority of DuoTrav APS over XALACOM® in Ocular Surface Health in patients with open angle glaucoma or ocular hypertension.
- Trial name
- NCT00912054
- Testing
- DuoTrav APS, Xalacom
- Where
- Belgium
- Volunteers
- 240 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma
The purpose of this study is to evaluate IOP response to experimental dose of Latanoprost- PPDS in subjects with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT00855517
- Testing
- Latanoprost-PPDS
- Sponsor
- Mati Therapeutics Inc.
Glaucoma, Ocular Hypertension
Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma
The purpose of this study is to determine the effect of artificial tears preserved with Benzalkonium Chloride (AT-BAK) on the IOP response to the L-PPDS and to evaluate the safety of the L-PPDS in subjects with OH or OAG…
- Trial name
- NCT00845299
- Testing
- Latanoprost punctal plug, artificial tears preserved with Benzalkonium Chloride
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mati Therapeutics Inc.
Glaucoma, Ocular Hypertension
A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).
This study will examine the efficacy and safety of Xalacom comparing with those of Xalatan in Japanese patients with POAG or OH, in order to show superiority of Xalacom over Xalatan in efficacy and similarity of safety between…
- Trial name
- NCT00383019
- Testing
- Xalatan, Xalacom
- Where
- 54 sites in Japan
- Volunteers
- 300 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Ocular Hypertension, Open-Angle Glaucoma
A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG
The objective of this study is to investigate how the intraocular pressure (IOP)-lowering effect of the L-PPDS is altered by adjunctive Xalatan therapy.
- Trial name
- NCT01037036
- Testing
- Latanoprost Punctal Plug Delivery System, Xalatan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mati Therapeutics Inc.
Open-Angle Glaucoma, Ocular Hypertension
Phase 3 Study Comparing IOP Lowering in OAG or OH in Japanese Subjects C-01-98
The purpose of this study is to evaluate safety and efficacy of two different IOP lowering medications after twelve months of treatment in Japanese subjects.
- Trial name
- NCT00047593
- Testing
- IOP Lowering Medications
- Where
- 3 sites in United States
- Sponsor
- Alcon Research
Open-angle Glaucoma, Ocular Hypertension
Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32
The purpose of this study is to evaluate safety and efficacy of two different IOP lowering medications after six weeks of treatment in Caucasian and Japanese subjects.
- Trial name
- NCT00047606
- Testing
- IOP Lowering Medications
- Volunteers
- 84 people
- Sponsor
- Alcon Research
Open Angle Glaucoma or Ocular Hypertension
A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study
The purposes of this study are to evaluate the long-term safety and intraocular pressure-lowering efficacy of DE-117 ophthalmic solution monotherapy and concomitant use of DE-117 ophthalmic solution with timolol ophthalmic…
- Trial name
- NCT02822729
- Testing
- DE-117 ophthalmic solution, Timolol ophthalmic solution
- Where
- Japan
- Volunteers
- 125 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Glaucoma, Ocular Hypertension (OH)
A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
The purpose of this study is to determine the effect of plug placement on the efficacy, safety and duration of effect of the L-PPDS (latanoprost punctal plug delivery system).
- Trial name
- NCT01481077
- Testing
- Latanoprost-PPDS
- Where
- 11 sites in United States
- Volunteers
- 77 people
- Sponsor
- Mati Therapeutics Inc.
Open Angle Glaucoma, Ocular Hypertension
Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health
The purpose of this study is to understand differences in visual function-related patient-reported outcomes between a non-BAK medication (Travoprost APS) and a BAK-preserved medication (XALATAN®) in patients with open-angle…
- Trial name
- NCT00892762
- Testing
- Travoprost APS 40 micrograms/ml eye drop solution, Latanoprost 50 micrograms/ml eye drop solution
- Volunteers
- 434 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma
The purpose of this study is to evaluate the effect of latanoprost on intraocular pressure reduction in patients with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT00647101
- Testing
- Latanoprost
- Where
- 176 sites in France
- Volunteers
- 600 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Ocular Hypertension
A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma
The purpose of this study is to determine if the Punctal Plug Delivery System is safe and effective in controlling intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT00820300
- Testing
- Latanoprost-PPDS
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Mati Therapeutics Inc.
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension
This study is to establish non-inferiority of a preservative free formulation of Bimatoprost ophthalmic solution 0.01% (YSBP) of YS Life Science Co., Ltd.
- Trial name
- NCT07661329
- Testing
- Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®)
- Where
- 22 sites in United States, India
- Volunteers
- 600 people
- Sponsor
- YS Life Science Co., Ltd.
Open-Angle Glaucoma, Ocular Hypertension
Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study was to compare the intraocular pressure (IOP)-lowering efficacy and safety of AZARGA™ (Brinzolamide 1%/Timolol 0.5% Ophthalmic Suspension), dosed twice daily versus AZOPT® (Brinzolamide 1% Ophthalmic…
- Trial name
- NCT01357616
- Testing
- Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension, Brinzolamide 1% ophthalmic suspension, Timolol 0.5% ophthalmic solution
- Volunteers
- 328 people
- Sponsor
- Alcon Research
Open Angle Glaucoma (OAG), Ocular Hypertension (OH)
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)
- Trial name
- TRIO (NCT07400926)
- Testing
- Travoprost
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Glaukos Corporation
Glaucoma, Ocular Hypertension
A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG
The purpose of this study is to evaluate the safety and preliminary efficacy of two formulations of the Latanoprost-PPDS in subjects with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT00967811
- Testing
- Formulation E1 of L-PPDS, Formulation E2 of L-PPDS
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Mati Therapeutics Inc.
Glaucoma, Ocular Hypertension
Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT
The purpose of the study is to compare the IOP lowering efficacy of Travoprost/Brinzolamide dosed daily in the morning or evening, vs TRAVATAN dosed once daily in the evening, and vs.
- Trial name
- NCT00767494
- Testing
- Travoprost/Brinzolamide fixed combination, Azopt, Travatan
- Where
- Belgium
- Volunteers
- 17 people
- Sponsor
- Alcon Research